WO2005015236A3 - A method for predicting the progression of adenocarcinoma - Google Patents

A method for predicting the progression of adenocarcinoma Download PDF

Info

Publication number
WO2005015236A3
WO2005015236A3 PCT/EP2004/007936 EP2004007936W WO2005015236A3 WO 2005015236 A3 WO2005015236 A3 WO 2005015236A3 EP 2004007936 W EP2004007936 W EP 2004007936W WO 2005015236 A3 WO2005015236 A3 WO 2005015236A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenocarcinoma
progression
predicting
kits
surgery
Prior art date
Application number
PCT/EP2004/007936
Other languages
French (fr)
Other versions
WO2005015236A2 (en
Inventor
Ruediger Rueger
Johannes Auer
Baerbel Porstmann
Martin Werner
Anja Wiese
Original Assignee
Roche Diagnostics Gmbh
Hoffmann La Roche
Ruediger Rueger
Johannes Auer
Baerbel Porstmann
Martin Werner
Anja Wiese
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh, Hoffmann La Roche, Ruediger Rueger, Johannes Auer, Baerbel Porstmann, Martin Werner, Anja Wiese filed Critical Roche Diagnostics Gmbh
Publication of WO2005015236A2 publication Critical patent/WO2005015236A2/en
Publication of WO2005015236A3 publication Critical patent/WO2005015236A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The present invention is related to a method for predicting the progression of adenocarcinoma, in particular colorectal cancer, after surgery whereby the level of expression of one or several gene markers is compared to a sample serving as control. Another method according to the invention is related to identifying an agent which will inhibit the progression of adenocarcinoma. The invention is further related to kits and arrays comprising the marker genes according to the invention.
PCT/EP2004/007936 2003-07-18 2004-07-16 A method for predicting the progression of adenocarcinoma WO2005015236A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03015667.3 2003-07-18
EP03015667 2003-07-18
EP03021130.4 2003-09-22
EP03021130 2003-09-22

Publications (2)

Publication Number Publication Date
WO2005015236A2 WO2005015236A2 (en) 2005-02-17
WO2005015236A3 true WO2005015236A3 (en) 2005-08-11

Family

ID=34137560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/007936 WO2005015236A2 (en) 2003-07-18 2004-07-16 A method for predicting the progression of adenocarcinoma

Country Status (1)

Country Link
WO (1) WO2005015236A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226915A1 (en) 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
US8008012B2 (en) 2002-01-24 2011-08-30 Health Discovery Corporation Biomarkers downregulated in prostate cancer
WO2005100606A2 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
EP1899482A2 (en) * 2005-04-07 2008-03-19 Novartis Vaccines and Diagnostics, Inc. Ddr2 in cancer diagnosis, detection and treatment
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
US20070037224A1 (en) * 2005-08-11 2007-02-15 Hamer Peter J Quantitative assays for PDGFR-beta in body fluids
EP1974058B1 (en) 2006-01-11 2014-06-11 Genomic Health, Inc. Gene expression markers for colorectal cancer prognosis
EP2041313B1 (en) * 2006-07-14 2011-03-23 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Methods of determining the prognosis of an adenocarcinoma
WO2008103265A2 (en) * 2007-02-16 2008-08-28 The Brigham And Women's Hospital, Inc. Methods of using ledgf/p75
JP2012525159A (en) 2009-05-01 2012-10-22 ジェノミック ヘルス， インコーポレイテッド Gene expression profile algorithms and trials in colorectal cancer recurrence and possible response to chemotherapy
JP5783909B2 (en) * 2009-12-16 2015-09-24 積水メディカル株式会社 Diagnostic method of malignant tumor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559019A (en) * 1994-06-22 1996-09-24 The Regents Of The University Of California Protein serine kinase, SRPK1
WO2002068677A2 (en) * 2001-02-27 2002-09-06 Eos Biotechnology, Inc. Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003021229A2 (en) * 2001-09-05 2003-03-13 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US20030073105A1 (en) * 2001-05-31 2003-04-17 Lasek Amy K.W. Genes expressed in colon cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559019A (en) * 1994-06-22 1996-09-24 The Regents Of The University Of California Protein serine kinase, SRPK1
WO2002068677A2 (en) * 2001-02-27 2002-09-06 Eos Biotechnology, Inc. Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
US20030073105A1 (en) * 2001-05-31 2003-04-17 Lasek Amy K.W. Genes expressed in colon cancer
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003021229A2 (en) * 2001-09-05 2003-03-13 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALON U ET AL: "BROAD PATTERNS OF GENE EXPRESSION REVEALED BY CLUSTERING ANALYSIS OF TUMOR AND NORMAL COLON TISSUES PROBED BY OLIGONUCLEOTIDE ARRAYS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, 1999, pages 6745 - 6750, XP000900484, ISSN: 0027-8424 *
GUI J-F LANE W S FU X-D: "A serine kinase regulates intracellular localization of splicing factors in the cell cycle", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 369, 23 June 1994 (1994-06-23), pages 678 - 682, XP002954878, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
WO2005015236A2 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2005015236A3 (en) A method for predicting the progression of adenocarcinoma
TW200741010A (en) Method for predicting the response to a treatment
WO2003089904A3 (en) Aib1 as a prognostic marker and predictor of resistance to encocrine therapy
WO2002024956A3 (en) Genetic markers for tumors
WO2006017083A3 (en) Methods and compositions for phenotype identification based on nucleic acid methylation
WO2007073171A3 (en) Improved strategies for transcript profiling using high throughput sequencing technologies
WO2004045547A3 (en) Rnai-based sensors, caged interfering rnas, and methods of use thereof
WO2005034845A3 (en) Compositions and methods for treatment of cancer
WO2005083429A8 (en) Breast cancer prognostics
WO2002061128A3 (en) Method of determining a chemotherapeutic regimen based on ercc1 expression
AU2002361908A1 (en) Methods for identifying marker genes for cancer
WO2005123942A3 (en) Analysis of methylated nucleic acid
EP1526186A3 (en) Colorectal cancer prognostics
MXPA06014175A (en) Diagnosing or predicting the course of breast cancer.
WO2008037700A3 (en) Methods for breast cancer prognosis
WO2004035748A3 (en) Methods using gene trapped stem cells for marking pathways of stem cell differentiation and making and isolating differentiated cells
WO2002065091A3 (en) Pin1 as marker for abnormal cell growth
WO2007023191A3 (en) Polypeptide marker for the diagnosis of bladder cancer
WO2004062487A3 (en) Methods of detecting gene expression in normal and cancerous cells
WO2005121946A3 (en) Inferring function from shotgun sequencing data
WO2005007097A3 (en) Breast cancer genes
WO2003007884A3 (en) Method and reagents for identifying gene targets for treating breast cancer
EP1355151A3 (en) Assessing colorectal cancer
EP1355149A3 (en) Assessing colorectal cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase